1. Home
  2. NCV vs SLN Comparison

NCV vs SLN Comparison

Compare NCV & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCV
  • SLN
  • Stock Information
  • Founded
  • NCV 2003
  • SLN 1994
  • Country
  • NCV United States
  • SLN United Kingdom
  • Employees
  • NCV N/A
  • SLN N/A
  • Industry
  • NCV Finance Companies
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • NCV Finance
  • SLN Health Care
  • Exchange
  • NCV Nasdaq
  • SLN Nasdaq
  • Market Cap
  • NCV 326.2M
  • SLN 352.2M
  • IPO Year
  • NCV N/A
  • SLN N/A
  • Fundamental
  • Price
  • NCV $3.51
  • SLN $6.88
  • Analyst Decision
  • NCV
  • SLN Strong Buy
  • Analyst Count
  • NCV 0
  • SLN 4
  • Target Price
  • NCV N/A
  • SLN $61.50
  • AVG Volume (30 Days)
  • NCV 405.1K
  • SLN 691.1K
  • Earning Date
  • NCV 01-01-0001
  • SLN 11-14-2024
  • Dividend Yield
  • NCV 12.48%
  • SLN N/A
  • EPS Growth
  • NCV N/A
  • SLN N/A
  • EPS
  • NCV N/A
  • SLN N/A
  • Revenue
  • NCV N/A
  • SLN $21,773,221.00
  • Revenue This Year
  • NCV N/A
  • SLN N/A
  • Revenue Next Year
  • NCV N/A
  • SLN $104.98
  • P/E Ratio
  • NCV N/A
  • SLN N/A
  • Revenue Growth
  • NCV N/A
  • SLN N/A
  • 52 Week Low
  • NCV $2.84
  • SLN $5.81
  • 52 Week High
  • NCV $3.59
  • SLN $27.72
  • Technical
  • Relative Strength Index (RSI)
  • NCV 41.63
  • SLN 32.78
  • Support Level
  • NCV $3.62
  • SLN $5.96
  • Resistance Level
  • NCV $3.61
  • SLN $8.88
  • Average True Range (ATR)
  • NCV 0.07
  • SLN 0.73
  • MACD
  • NCV -0.03
  • SLN 0.27
  • Stochastic Oscillator
  • NCV 19.64
  • SLN 33.77

About NCV Virtus Convertible & Income Fund of Beneficial Interest

Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Share on Social Networks: